HIV peripheral neuropathy progression: protection with glucose-lowering drugs?
The purpose of this study is to evaluate risk factors for progression from asymptomatic peripheral neuropathy (APN) to symptomatic peripheral neuropathy (SPN). Antiretroviral therapy (ART)-naïve patients initiating combination ART were followed longitudinally and screened for signs/symptoms of PN. Having APN was associated with higher odds of future SPN (odds ratio (OR) = 1.58, 95 % confidence interval (CI) = (1.08, 2.29), p = 0.027). Neurotoxic ART use was associated with increased odds of progression to SPN (OR = 2.16, 95 % CI = (1.21, 3.85), p = 0.009) while use of glucose-lowering drugs (non-insulin) was protective (OR = 0.12, 95 % CI = (0.02, 0.83), p = 0.031). Use of glucose-lowering drugs (non-insulin) may prevent progression from APN to SPN.
Center for Biostatistics in AIDS Research, Department of Biostatistics, FXB-513 Harvard School of Public Health, Boston, MA 02115, USA.
Scott R
SR
Evans
Anthony J
AJ
Lee
Ronald J
RJ
Ellis
Huichao
H
Chen
Kunling
K
Wu
Ronald J
RJ
Bosch
David B
DB
Clifford
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D058070:Asymptomatic Diseases; D001786:Blood Glucose / Q000378:metabolism; D002648:Child; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010523:Peripheral Nervous System Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D012307:Risk Factors
D019380:Anti-HIV Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents